Compare · ABSI vs CRL
ABSI vs CRL
Side-by-side comparison of Absci Corporation (ABSI) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.21B, about 8.6x ABSI ($1.65B).
- Over the past year, ABSI is up 278.8% and CRL is up 81.7% - ABSI leads by 197.0 points.
- CRL has been more active in the news (17 items in the past 4 weeks vs 6 for ABSI).
- CRL has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Charles River Laboratories International Inc.
- Price
- $9.64+8.80%
- $297.55-0.34%
- Market cap
- $1.65B
- $14.21B
- 1M return
- +27.68%
- +32.71%
- 1Y return
- +278.78%
- +81.73%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2000
- News (4w)
- 6
- 17
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest ABSI
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- SEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake
- SEC Form 3 filed by new insider Somaratne Ransi Mudalinayake
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
Latest CRL
- Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)
- Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- Chief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.
- EVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)
- Director Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)